Exosomes are cellular secretory vesicles containing microRNAs (miRNAs). Once secreted, exosomes are able to attach to recipient cells and release miRNAs potentially modulating the function of the recipient cell. We hypothesized that exosomal miRNA expression in brains of patients diagnosed with schizophrenia (SZ) and bipolar disorder (BD) might differ from controls, reflecting either disease-specific or common aberrations in SZ and BD patients. The sources of the analyzed samples included McLean 66 Cohort Collection (Harvard Brain Tissue Resource Center), BrainNet Europe II (BNE, a consortium of 18 brain banks across Europe) and Boston Medical Center (BMC). Exosomal miRNAs from frozen postmortem prefrontal cortices with well-preserved RNA were isolated and submitted to profiling by Luminex FLEXMAP 3D microfluidic device. Multiple statistical analyses of microarray data suggested that certain exosomal miRNAs were differentially expressed in SZ and BD subjects in comparison to controls. RT-PCR validation confirmed that two miRNAs, miR-497 in SZ samples and miR-29c in BD samples, have significantly increased expression when compared to control samples. These results warrant future studies to evaluate the potential of exosome-derived miRNAs to serve as biomarkers of SZ and BD.
Introduction
Knowing which molecules are specifically altered in neuropsychiatric patients would represent a crucial step towards uncovering mechanisms of the development of neuropshychiatric diseases and generating more successful therapeutic strategies. An immediate impact of identifying such molecules would be access to a set of biomarkers to help define and monitor populations at risk.
MicroRNAs (miRNAs, miRs) may up-or down-regulate the translation of messenger RNA (mRNA) or render it unstable, and have recently been proposed as biomarkers for brain neoplasms, degenerative diseases, autism, and schizophrenia [1] . Dysregulation of miRNAs in brains of patients diagnosed with schizophrenia (SZ) [2] and other neuropsychiatric disorders is plausible considering that many miRNAs are expressed in human brain [3] where they regulate neuronal development [4] and differentiation [5] including dendritic spine development [6] and plasticity [7] , [8] , as well as cognitive functions [9] . A group of miRNAs has been recently designated as ''misexpressed'' in the prefrontal cortices (PFCs) of both SZ and bipolar disorder (BD) patients [10] . The target analysis of another reported set of differentially expressed miRNAs in the PFCs of SZ patients revealed many genes implicated in signaling pathways [11] . While a specific BD miRNA profile has not yet been established, alterations in neurochemical regulation including an excess in signaling activity have been associated with BD [12] .
Signaling activity in neurons commonly requires the release of signaling molecules from their specific secretory vesicles [13] . Exosomes are secretory vesicles defined by size (30-90 nm) , buoyant density (,1.1-1.2 g/ml), lipid composition, and the presence as well as the absence of specific marker proteins [14] .
Exosomes represent the alternative route for the content of multivesicular bodies (MVBs, exosomal precursor organelles) destined for degradation in lyzosomes. Rather then being degraded, MVBs' intraluminal vesicles are fused with the plasma membrane and secreted into the extracellular space as exosomes [15] . Because of the specific molecules on their surface, including cell-adhesion proteins, exosomes can be incorporated by specific recipient cells [15] , [16] . The exosomal involvement in neuronal signaling was suggested by the presence of MVBs in dendritic spines [17] , [18] and by the resemblance of synaptic spinules (evaginations of the postsynaptic membrane that bud into presynaptic axon) to exosomes [19] , [20] . The role of exosomes in synaptic activity is further corroborated by the dependence of long term potentiation (LTP)-induced structural spine plasticity on exocytic trafficking from recycling endosomes [21] .
Cultured primary cortical neurons and astrocytes do release exosomes [22] . Studies of exosomal cargo in neurons and microglia have revealed proteins important for the development of neurodegenerative diseases such as Alzheimer's disease [23] [24] [25] [26] and Parkinson's disease [27] . Exosomes in neuronal cell lines have also been shown to transfer prions [28] as well as wild-type and mutant superoxide dismutase, thus propagating cell-to-cell mutant toxicity [29] . Microarray analysis of exosomal content from mouse bone marrow mast cells and human and mouse mast cell lines has established the presence of mRNA and miRNA [30] . A new name for this mRNA -''exosomal shuttle RNA'' [30] -has been proposed to underscore the ability of exosomes to mediate the exchange of genetic material between cells. Changes in exosomal miRNAs have been reported in patients diagnosed with Alzheimer's disease [31] , while RNA content from the glioblastoma microvesicles was shown to provide diagnostic biomarkers [32] . Postmortem human PFC samples have been used to successfully generate miRNA profiles [11] . Here we report the results of exosomal miRNA expression analysis in PFCs from patients diagnosed with SZ, BD, and mental illness-free controls. We have observed aberrations in SZ and BD samples in comparison to controls, suggesting both common and differential pathobiology. These results may forecast reproducible, disease-associated changes of miRNA expression serving as biomarkers in exosomes, cellular particles potentially obtainable from the cerebrospinal fluid (CSF) of living patients.
Materials and Methods

Human Brain Tissue
Written informed consent was obtained from the next of kin for the use of the postmortem brain tissue by the following sources of frozen PFC (Brodmann area 9, BA9): BrainNet Europe II, a consortium of 18 brain banks across Europe (BNE; cases SZ 1-6, BD 5-9, and C 6-10), McLean 66 Cohort Collection at Harvard Brain Tissue Resource Center (McLean; cases SZ 7 and 8, BD 1-4, and C 1-5), and autopsy service at Boston Medical Center (BMC; cases C 11-13) ( Table 1) .
Extractions of Exosome-containing Pellets
Exosome extraction protocol from primary and cultured cells [30] was modified to obtain exosome-containing pellets from frozen brain tissue that was previously evaluated for RNA integrity ( Figure S1 ). Only the brain tissue samples yielding an RNA integrity number (RIN) of $5.1 (range 5.1-9.1, Table 1 ) and thus well within accepted standards [33] were used to obtain exosomecontaining pellets. From the original frozen prefrontal cortex stored at 280uC procured by each brain bank, we cut approximately 600 mg of grey matter using a razor blade. The frozen tissue was put in 1 ml phosphate-buffered saline, pH 7.4 (PBS, 4uC), gently teased with a small spatula, and vortexed (VWR mini-vortexer) on a medium power. Each tube was centrifuged at 3006g for 10 min, decanted, centrifuged twice at 1,2006g for 10 min with decanting in between, and finally filtered through a 0.2 um syringe filter (Millipore, Carrigtowhill, Cork, Ireland). The filtrate was centrifuged twice at 10,0006g for 30 min with decanting in between. The final centrifugation to obtain exosome-containing pellets was performed at 22,0006g for 22 hrs. All centrifugations were performed at 2uC.
As a control exosomal extraction procedure, exosomes from cultured human H4 cells (HTB 148 ATCC, Manassas, VA, USA) were prepared as previously published [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] with minor modifications. Briefly, H4 cells were cultured in OPTIMEM medium (Life Technologies) without serum or antibiotics. After 48 hours, conditioned medium was collected and centrifuged for 5 min at 5006g at 4uC to remove cell debris. The supernatants were then sequentially centrifuged at 3006g (10 min) and twice at 2,0006g (10 min), 4uC. The supernatant was filtered through a 0.45 um (Whatman, Florham Park, NJ) and 0.22 um (Millipore, Carrigtowhill, Cork, Ireland) filter, and centrifuged for 1 hr at 10,0006g at 4uC. The supernatant was removed and then subjected to ultracentrifugation at 100,0006g for 2 hours at 4uC. The supernatant was collected and the exosome-containing pellet was re-suspended in PBS for Western Blotting.
Transmission Electron Microscopy (TEM) and Immunogold Labeling
For morphological identification of exosomes, the pellets were either embedded in a hydrophilic resin upon fixation in TEM fixative (4% paraformaldehyde, 0.2% glutaraldehyde, in 0.2 M cacodylate buffer, pH 7.2.) or directly adsorbed to a carboncoated grid that has been made hydrophilic by an exposure to a glow discharge (30 sec). Upon blocking with 1% Bovine Serum Albumin (BSA), grids with pellets were incubated in primary antibody (CD63, BD Pharmingen, and GAPDH, Ambion) solutions in 1% BSA, rinsed in PBS, exposed to either bridging antibody first or directly to protein A-gold (5 nM) solution in 1% BSA, rinsed in PBS, and finally in water. Excess liquid was removed with a filterpaper (Whatman #1). Optional negative staining was achieved by incubation in 0.75% uranyl formate for 30 seconds. The examination was carried out in a JEOL 1200EX TEM or a TecnaiG 2 Spirit BioTWIN and images were recorded with an AMT 2k CCD camera.
Western Blotting
The expression of an exosomal marker flotillin-2 [35] in the exosomal preparations from frozen postmortem PFC was compared to the flotillin-2 expression in the cell-culture-derived exosomal preparations described above. Equal protein amounts (2.5 mg/ml) from each exosome-containing pellet reconstituted in PBS and respective supernatant were blotted with anti-flotillin-2 antibody (BD Transduction Laboratories, 1:1,000).
Isolation, Purification, and Linear Amplification of miRNA from Exosome-containing Pellets
Exosome-containing pellets re-suspended in 20 ul of PBS were incubated with 0.4 mg/ml of RNase A/T1 (Fementas) for 10 min at 37uC. RNase was inactivated by adding 20 units/ul of SuperRase-in RNase inhibitor (Ambion) for 10 min at 25uC. The RNase treatment destroyed the higher molecular weight extra-exosomal cellular RNAs and preserved the small RNAs contained in the exosomes, i.e. ribosomal RNA and miRNA ( Figure S2 ). Upon RNase inactivation, 60 ul of miRNA extraction buffer (Arcturus) was added, followed by an incubation at 42uC for 30 min and purification using PicoPure RNA Isolation Kit (Lifetech). The expected size range of miRNAs (,19-28 nucleotides, nt) and pre-miRNAs (45-60 nt) were well-represented in the purified preparations ( Figure S2 ). Because Luminex profiling system operates with inputs of 2.5-5 ug of total RNA per sample, we needed to ensure that our samples are sufficiently enriched for miRNA. To that end, we used Invitrogen NCode miRNA amplification system according to the manufacturer's protocol to linearly amplify miRNA in our material (Table S2) . We found that this amplification step upon above described RNA treatment did not induce changes in the RNA profile ( Figure S3 ). We performed miRNA expression analysis using a FlexMAP3D instrument by (Luminex Corporation, Austin, TX) and a manufacturer's assay for 312 miRNA (Table S1 ). This assay uses 5.6 um polystyrene micro-beads each of which contains a mixture of two fluorescent dyes that enable the beads to be identified as one of a specific set. Oligonucleotides, specific for each of our 312 miRNA assayed, were attached to the beads according to the manufacturer's protocol. The beads, upon incubation with miRNA containing samples, were passed through a fluidic tube that causes the micro-spheres to line up in single file before they pass through the detection chamber that contains two lasers. One of the laser beams classifies each bead into the appropriate bead set, while the other scans the beads for the presence of fluorescent reporter molecules and quantifies the number of reporter molecules on each bead. All 312 miRNA were assayed simultaneously in each sample. Intra-normalization of the obtained expression values was performed according to the Luminex protocol. Negative values were considered ''0'' because they indicate the expression below the background, i.e. the absence of a specific miRNA signal (Table S1 ).
Statistical Analysis of Luminex miRNA Expression Data
Student's t-tests and statistical software packages including an Excel plug-in named Significance Analysis of Microarrays (SAM) [36] , [37] and an R package named Prediction Analysis of Microarrays (PAM) [38] were used to analyze Luminex expression data on 312 miRNAs from the prefrontal cortex of 8 SZ, 6 BD, and 6 control samples (Table 1 and Table S1 ). Because the statistical analysis of these data involves multiple comparisons we applied Bonferroni Step-down Holm Correction [39] to Student's t-test outcomes [0.05/(312-number of miRNAs ranked higher)], resulting in a stricter threshold for significance (Table S1 ). Next, we used SAM and PAM because they provide multiclass testing [36] [37] [38] while a simple t-test only enables analysis between two groups. Multiclass testing was a necessary tool to identify a set of miRNAs that could be used to differentiate between all three groups. Both SAM and PAM use a modified z-score statistic [36] [37] [38] to produce a ranked list of candidate biomarker miRNAs. The adjustment for codependency of expression was performed as local False Discovery Rate (FDR) [37] , [40] presented in Tables 2 and  3 . FDR is a method of permutation testing [41] that evaluates the risk of Type 1 error. Local FDR is an FDR assessment of not only a single miRNA, but also its ''neighbors'', i.e. other closely ranked miRNAs. In this way, a co-dependency is accounted for. Cluster analysis [38] was applied to those miRNAs that had ''00 q-values in SAM (Tables 2 and 3 ). Clustering was carried out through use of 2*(1-cc) where cc equals a correlation between the cubed root of a single miRNA expression value for a sample and the average of cube-rooted values for all samples in the cluster it joins at that time point. The highest possible correlation between samples is 1 and the lowest is 0, resulting in a dendrogram that presents the clustered samples on a scale of 0 to 2. The dendrogram begins clustering miRNA with most similar expression patterns at the bottom of the graph and then additional miRNA are added to existing clusters as the graph is assembled vertically. In order to assess the predictive power of SAM-ranked miRNAs, the misclassification rate [38] [39] [40] [41] [42] was established as a means to classify clinical groups. A low misclassification rate indicates that a miRNA or a set of miRNAs is a reliable predictor of a group phenotype (a biomarker). Because of the limited number of cases available for analysis, we performed Wilcoxon test to supplement our findings (Table S3) . Upon isolation and purification of RNA from exosomecontaining pellets as above, the RNA concentration of each sample tested (Table 1) was calculated using Agilent Bioanlyzer 2100 data. 20 ng of RNA was used to synthesize cDNA in a 20 ul reaction volume employing Exiqon mIRCURY LNA microRNA PCR Universal cDNA Synthesis Kit (Denmark). Quantitative PCR (qPCR) reactions for miRNAs of interest were performed according to the same manufacturer's protocol. Briefly, cDNA was diluted to a final concentration of 0.1 ng/ul, added to a primer set generated by Exiqon and PCR SYBR Green Master Mix by the same manufacturer, and run for 40 cycles on a Bio-Rad iCycler. To obtain a change in CT (Delta-CT) for each miRNA of interest we needed to have an internal control in every sample. Luminex data as well as preliminary qPCRs established that miR-423 had a stable and robust expression in the samples tested (Table S1 ). Thus, all the analyzed samples were run in duplicates for each miRNA of interest and for miR-423 as a reference [43] [44] [45] , (http://www. exiqon.com/ls/Documents/Scientific/miRNA-qPCR-guidelines. pdf) in a minimum of three separate plates. In each plate, the average CT value for miR-423 was subtracted from average CT value for a given miRNA of interest to obtain a value of change in CT (Delta-CT) for every sample. Student's t-tests on control and BD and on control and SZ Delta-CT values were performed using Graph Pad Prism 5.
Results
Exosomal Marker Identification in Exosome-containing Pellets from Postmortem Human Prefrontal Cortex
To confirm the presence of exosomes in our pellet-preparations from postmortem human frozen BA9 cortices, we examined the morphology and antigenicity of the pellet content ( Figure 1 ). On electron microscopy, membrane-bound vesicles with diameters of 70-90 nm were immunoreactive for antigens commonly found in exosomes, CD63 and GAPDH ( Figure 1A and B) . Next, we evaluated the efficiency of our exosomal extractions from brain tissue. Western blot analysis revealed the presence of flotillin-2, protein commonly associated with exosomal membrane [35] , in both BA9 pellets and in exosomes-containing pellets from the medium of cultured H4 cells ( Figure 1C ). The exosomal extraction procedures depleted flotillin-2 from the supernatants ( Figure 1C ). The list of 198 miRNAs were narrowed from 312 microRNA using a linear regression model and subsequently ranked by z-score test statistics. Local FDR evaluates false discoveries by assigning samples to random groups to test for statistical significance by chance. The relevance of FDR is determined using qvalues, an analog of the p-value. The 21 top-ranked miRNAs have a q-value equal to 0%, meaning that it is highly unlikely for this miRNAs to be expressed differentially by chance among the three groups examined. SZ = schizophrenia; BD = bipolar disorder; C = controls. doi:10.1371/journal.pone.0048814.t002 Luminex miRNA expression data in exosome-containing pellets from prefrontal (BA9) gray matter of 8 SZ patients (SZ 1-8), 6 BD patients (BD 1-6), and 6 controls (C 1-6) ( Table 1) were submitted to Student's t-test. These data reveal several significantly differentially expressed miRNAs in either BD or SZ, or both in comparison to controls. Bonferroni Step-down Holm Correction was then applied to correct for multiple comparisons [39] . This correction resulted in the absence of significantly differentially expressed miRNAs in BD samples, while the expression of only three miRNAs (miR-31, -33, and -96) was significantly enhanced in SZ samples in comparison to controls and to BD (Table S1 ). In an alternative statistical approach towards identification of miRNAs differentially expressed in the three groups examined, we submitted raw Luminex miRNA expression data to Significance Analysis of Microarrays (SAM) program [36] , [37] (Table 2) . SAM ranked the expressions of examined miRNA expression using zscores (Table 2 ). For the 21 top-ranked miRNAs, Prediction Analysis of Microarrays (PAM) [38] -derived q-value was 0% (Figure 2 ). We next examined how the expression of these 21 topranked miRNAs might influence the clustering of our samples. Surprisingly, the dendrogram from the clustering analysis [38] ( Figure 3) suggests that the expression the 21 top-ranked miRNAs segregated SZ samples from BD samples and controls, leaving BD samples and controls undifferentiated from one another. In order to remove the influence of SZ group on the ranking system, the SAM program was run again for BD and control groups only (Table 3 ) and yielded 7 miRNAs with q-value of 0% (Table 3) . This group of miRNAs, however, had a rather limited ability to segregate BD samples from controls (cluster dendrogram not shown). These results prompted us to submit the entire Luminex data to a PAM-derived misclassification rate analysis to determine if the miRNA expression values of each sample in a group have a reliable predictive power, i.e. if they can serve as biomarkers for a given group [42] - [38] . The misclassification rate was 0 for the SZ group (Figure 4 ), indicating that: a) the examined miRNA expressions were tightly grouped in SZ as previously indicated by the cluster dendrogram (see Figure 3) ; and b) the expression values of a very small number of miRNAs can assign an SZ sample to its correct group. The control samples had most variable miRNA expression levels associated with high misclassification rate regardless of how many miRNAs were evaluated (Figure 4) . Finally, Figure 4 shows that the misclassification rate for BD samples is dependent on the number of miRNAs evaluated: if ,13-16 miRNAs are taken into account, BD samples separate well from controls and reach zero misclassification rate that is characteristic of SZ samples (Figure 4 ).
Covariate Analysis: the Effect of Medications on SAM Results
The clinical information accompanying our samples failed to provide sufficient data to control for tobacco, alcohol or recreational drug consumption (Table S4) , while the information of prescribed medications (Table 4 ) was well defined. The cases were marked if the patients took at least one medication from the seven drug classes constructed on the basis of the common mechanism(s) underlying drug effect (A-G; Table 5 ). Since a standard error is used to generate a covariate effect, only drug classes with at least three case-subjects taking a drug and three case-subjects not taking a drug could be evaluated as covariates. Thus, only drug classes A (antipsychotics used in SZ only), B (neurotransmitter receptor-site binders used in both BD and SZ), and C (sedatives, hypnotics, anticonvulsants and analgesics used in both BD and SZ) could be controlled for. In a simple format of covariate adjustment [46] the effects of multiple independent variables are added together in a linear regression model. To guard against Type I errors, we designed a model to adjust for covariates using the SAM program. SAM was rerun to compare case subjects taking a specific drug class medication against case subjects not taking it, and a list of covariate effects for drug classes A-C was derived for top-ranked miRNA in the study (Table 6) . Those effects were then subtracted from the original z-scores (Tables 2 and 3 ) and p-values were added to demonstrate the effects of the covariate on significance (Tables 7 and 8) .
When adjusted for drug class A (antipsychotics used in SZ only), the significance of results for miRNAs 31, 33, 96, 30e-5p, and 199a* was preserved, while miRNAs 15b, 455, 32, and 20b acquire significance (Table 7, see also Table 2 ). After the adjustment for B (neurotransmitters receptor-site binders) and C (sedatives, hypnotics, anticonvulsants and analgesics) drug classes in SZ subjects, the significance for miRNAs 31, 33, 96, 30e-5p, and 199a* was still preserved while miR-455 (again) acquired significance together with miR-323 ( Table 7, see also Table 2 ). In BD subjects, the consideration of combined effects of B and C drug classes heightened the significance of the results for miRNAs 219 and 29c while miRNA 30e-3p and 526b* acquired significance (Table 8, see also Table 3 ). Importantly, Wilcoxon test also indicated the expression of miRNAs 219 and 526b to be significantly different in BD cases in comparison to controls, but failed to discover miRNA 29c (Table S3; see Discussion) .
Finally, while effects related to gender were not relevant to this study due to a male dominated cohort, we did consider the ages of our cases (Table 1) . Although the SZ group of cases is on average older than BD and control groups, no significant difference in age between groups exists (Table S5) .
qPCR Analysis Confirms Differential Expression of miR-497 in SZ, and miR-29c in BD Samples in Comparison to Controls
To verify microarray data for miRNAs that may be differentially expressed in our three analyzed groups, controls, BD, and SZ, we performed a series of qPCR experiments. The primers for the following miRNAs worked in reactions with cDNA derived from each of our samples available for analysis: miR-31, -15b, -29c, -497, -219, and -149. These miRNAs were among the highest ranked according to the likelihood to be differentially expressed in both SZ and BD (miR-31, -15b, -29c, and -497; Table 2 ), or just BD (miR-219 and -149; Table 3 ). To further test the reproducibility of our data we used additional BD and additional control cases that became available through brain banks and BMC autopsy service (Table 1) : SZ 1-6 (same as in Luminex experiment), BD 5-9 (three new samples), and C 6-13 (seven new samples). As shown in Table 9 and Figure 5 , qPCR analyses confirmed miR29c to be significantly differentially expressed (2.77 fold increased) in the examined BD samples, and miR-497 in SZ samples (2.35 fold increased) in comparison to controls.
Discussion
While genetic component has been extensively researched in BD and SZ patients, the biological markers for these diseases have proven remarkably elusive. The putative susceptibility genes in both BD and SZ regulate cell-signaling [47] [48] . This study analyzed the expression of miRNAs found in exosomes ( Figure 1A and B), signaling vesicles capable of cell-to-cell transfer of miRNAs, in the prefrontal cortices of patients diagnosed with either BD or SZ and of individuals with no mental illnesses.
Standard statistical analysis (Student's t-test with Bonferroni
Step Down/Holm correction) of the results of Luminex oligonucleotidebased screen for the expression of 312 miRNAs revealed only three miRNAs differentially expressed in SZ in comparison to BD and control samples (Table S1 ). While these three miRNAs (miR-31, -33, and -96) were also most highly ranked in a z-score based SAM, an additional 18 miRNAs were suggested to have truly differential expression (Table 2) . Accordingly, the expression values of about 21 miRNAs were not false discoveries in a threeway comparison (Figure 2 ). These 21 miRNAs distinguished SZ but not BD samples from controls relatively well (Figure 3 ). Upon elimination of the distinctive influence of SZ samples in the threeway comparison (Table 2) , the short list of most differentially expressed miRNA in BD compared to controls (Table 3) still featured several of the original top 21-ranked miRNAs. The covariate adjustment for the medications used by some of the subject cases (Tables 4 and 5 ), had nominal effects on significance of differential miRNA expression in the SZ group, while in the BD group the difference in the expression of miR-30e-3p, -219 and29c attained heightened significance (Tables 6-8) . To verify the microarray data, we performed qPCR analysis of the selected miRNAs in a partially new set of samples. Two miRNAs were Table 4 . Medications (grouped in classes A-G) prescribed to subject cases for psychiatric and neurological symptoms. confirmed to have significantly altered expression: in comparison to controls, the expression of miR-497 and miR-29c were significantly higher in SZ samples and BD samples, respectively (Table 9) .
Our study has several novel and important findings. While exosomal content has been intensively studied in human diseases ever since the report of Valadi et al. in 2007 [30] , we demonstrated here for the first time that exosomal miRNAs could Table 5 . Classes (A-G) encompassing the medications in Table 4 . be obtained from frozen postmortem brain tissue. On electron microscopy our PFC-derived exosome-containing pellets showed membrane bound vesicles within the range of the reported size of exosomes [49] ( Figure 1A and B) . In addition to the identification by size, shape, and miRNA content (intracellular micro-vesicles of similar size, e.g. lysosomes, do not contain miRNAs), we demonstrated a robust signal for CD63 and GAPDH in the micro-vesicles extracted from the human PFC ( Figure 1A and B). According to Mathivanan and Simpson (2009) [50] exosomes from different sources have varying sets of protein markers on their surface, with CD63 being the second most, and GAPDH being the fourth most commonly reported exosomal antigen. Finally, our exosome-containing pellets were enriched with exosomal marker flotillin-2 [35] on Western blots, similar to the pellets from the medium of cultured cells ( Figure 1C ). Having insight into the cortical exosomal miRNA content may be of particular importance because exosomes are released into the CSF, and thus accessible for evaluation in living patients [51] . A recent study identified a substantial number of miRNAs exclusively or predominantly expressed in CSF [52] . Comparing the data from brain tissue with CSF will indeed require clinical investigation since postmortem brain depositories do not currently have sufficient number of samples and/or amount of CSF from neuropsychiatric patients. So far, the search for specifically altered miRNA expression in peripheral blood mononuclear cells (PBMCs) in SZ yielded diverse results [53] , [54] . Three miRNAs were found to be differentially expressed in PBMCs as well as in PFC (BA46) of SZ patients [53] [54] [55] .
The second novel and important feature of our investigation lies in the fact that our statistical analyses pointed to both differences and similarities between the miRNA expression changes in SZ and BD samples in comparison to control samples. The SAM top 21-ranked miRNAs (Table 2, Figure 2) had the ability to separate SZ samples, but not BD samples from the controls (Figure 3 ). This finding is directly connected to the suggested inherent differences in the variability of miRNA expression values in control samples in the three analyzed groups of samples, illustrated by the misclassification error rate analysis (Figure 4) . The high variability of miRNA expression values in control samples represents perhaps a defining feature -the agility of the cortical transcriptional regulation in the absence of mental disease.
Initial statistical analysis revealed three miRNAs (miR-31, -33, and -96) differentially regulated in SZ samples (Table S1 ). Of those three, miR-33 was previously reported among misexpressed miRNAs in PFCs of both SZ and BD individuals [10] . Since we performed qPCR for additional miRNAs that were likely to be differentially expressed in SZ and BD samples according to SAM (Tables 2 and 3) , we found significantly increased miR-497 expression in exosome-containing pellets from PFCs of SZ patients (Table 9) . Perkins et al. (2007) [11] reported 16 miRNAs to be differentially expressed in PFCs of SZ subjects, one being miR-195. Both miR-195 and -497 belong to the well-studied miR-15/ 107 gene family. miR-15/107 miRNAs share most of their targets and are implicated in the pathogenesis of neoplasms, neurodegenerative diseases and heart disease [56] . Importantly, the upregulation of these miRNAs expected to affect cortical gene expressions, has been reported in SZ [57] . Interestingly, miR-497 was also found to promote ischemic neuronal death by negatively regulating anti-apoptotic proteins, bcl-2 and bcl-w [58] . Three more miRNAs from our SAM top 21-ranked miRNAs were on the list of significantly down-regulated miRNAs in SZ by Perkins and colleagues [11] : miR-92, -20b, and -30e. miR-92 and -20b belong to miR-17-92 cluster known to be a potent oncogene [59] . Potentially pertinent for SZ pathobiology, miR-92 has also been suggested to developmentally regulate neuronal K(+)Cl(2) cotransporter 2 (KCC2) that modulates effects of GABA [60] . Finally, miR-30e may regulate neuronal death as down-regulation of miR-30e expression promoted neuronal survival in long-lived calorie-restricted mice [61] . However, we were not able to validate differential expression of miRNA-30e in the exosome-containing samples of PFCs in SZ (data not shown). We found miR-29c to be significantly increased in the exosome-enriched preparations from PFC of individuals diagnosed with BD in comparison to controls according to SAM and qPCR analysis. Interestingly, the expression of miR-29c was not significantly different in BD cases compared to controls according to Wilcoxon test applied to our Luminex data (p-value 0.0649; Table S3 ). The fact that miR-29c was significantly differentially expressed in SAM (Tables 2 and 3) , further confirmed by qPCR analysis in BD vs. controls ( Table 9 ), suggests that FDR testing through the use of SAM might be a superior strategy for discovery of true positives.
Like miR-497, the miRNA confirmed to be up-regulated in SZ samples, miR-29c was among the top-ranked in both SAM analyses (Table 2 and 3) . In other words, both of these miRNAs were considered highly differentially regulated in both diseases according to SAM. Moreover, miR-29c was also reported by Table 6 . Covariate effects of medications on highly-ranked miRNAs in SAM (top-21 in Table 2 and top-12 in Table 3 ). Table 7 . Top-ranked miRNAs from The significance of results for miRNAs 31, 33, 96, 30e-5p, and 199a* (bold) was preserved (see Table 2 ), while miRNAs 15b, 455, 32, and 20b acquire significance (bold) after the adjustment for the drug class A (antipsychotics used in SZ only). After the adjustment for drug classes B (neurotransmitters receptor-site binders) and C (sedatives, hypnotics, anticonvulsants and analgesics) drug classes, the significance for miRNAs 31, 33, 96, 30e-5p, and 199a* (bold) was again preserved (see Table 2 ) while miR-455 acquired significance together with miR-323 (bold). SZ = schizophrenia. doi:10.1371/journal.pone.0048814.t007
Perkins et al. to be differentially expressed miRNAs in PFC of SZ patients [11] . Interestingly, miR-29 together with miR-31, the topranked differentially expressed miRNA by SAM but not by qPCR (Table S1, Table 8 ), was proposed to regulate several cell-adhesion machinery components that are affected in the pathogenesis of many diseases [62] . The up-regulation of miR-29c in the cortical exosomes of BD patients is particularly intriguing because miR29c is induced by canonical Wnt signaling [63] that is antagonized by GSK-3, a know substrate of inhibition by lithium, a first line of therapy for BD [64] . The interpretation of our findings has the following limitations. First, the relationship between exosomal and cellular miRNAs is not understood: is the exosomal miRNA aberration a part of pathogenesis, or a corrective attempt? Second, age-associated common brain pathology, may complicate the interpretation of our results, although vascular and early Alzheimer's diseaseassociated pathologies were relatively evenly distributed in our samples (Table 1) . Third, we were limited by a finite number of the samples available that fulfilled the RNA quality standards. However, the statistical methods we applied were developed specifically as a ''non-parametric'' test for miRNA expression studies. This test has a built-in mechanism for evaluating small sample sizes, and makes use of a ''positive constant'' standard error value as one of its formulaic variables. This ensures that miRNAs with small values are not elevated high in the rankings simply because they have a small standard error. By comparison t-tests often assign strong significance to miRNAs with small expression levels due to their small standard errors. The PAM and SAM programs we used are therefore optimal in dealing with irregular data with small sample size such as ours.
Fourth, our microarray examined the expression of 312 miRNA, while hundreds more are known to exist and thus may be important for the pathobiology of SZ and BD. Finally, due to the variable efficiency of the primers in our cDNA samples, we could carry qPCRs for only six miRNAs (Table 8, 9 ) featured among our top-ranked in SAM analyses (Tables 2 and 3) . The consideration of combined effects of B and C drug classes heightened the significance of the results for miRNAs 219 and 29c (bold; see Table 3 ), while miRNA 30e-3p and 526b* (bold) acquired significance. BD = bipolar disorder. doi:10.1371/journal.pone.0048814.t008 Nevertheless, the results of qPCR validation are remarkable considering that we examined different samples from the ones analyzed in the microarray, in particular controls -most likely to exhibit highly variable miRNA expressions (Figure 4) . Interestingly, our qPCR analysis did not validate SZ-associated highly significant up-regulation of miR-31 by Luminex assay ( Table 2,  Table S1 ). Considering, however, that Gardiner et al. (2012) [54] confirmed miR-31 down-regulation in PBMCs of SZ patients, miR-31 dysregulation in SZ cannot be ruled-out. Our search for exosome-derived biomarkers yielded two candidates, miR-497 and miR-29c, in the PFC of SZ and BD patients respectively, potentially offering a novel insight into the pathogenesis of these diseases. In addition, rapid development of exosome nanotechnology [65] adds the promise of alternative therapeutics delivery [66] [67] to the emerging diagnostic potential of brain-derived exosomes in neuropsychiatric diseases.
Supporting Information
Figure S1 RNA quality control. Representative RNA (sample C13, RIN = 7.0; the sample closest to the average (6.96) and median (6.85) value for the set) yields two strong bands at 40 s and 45 s representing the 18 S and 28 S ribosomal RNA (A). The electropherogram shows a marker peak and the two ribosomal peaks corresponding to 18 S and 28 S subunits. RIN value on a scale of 1-10 is computed based on the presence of correct ribosomal peaks, the ratio between those peaks, and the extent of RNA fragmentation (B). Relationship between RIN and mRNA and miRNA profiles Table 3 , with qvalues lower than 15%, ending with miR-526b* -the last miRNA 
